NCT01850680View on ClinicalTrials.gov

Single Ascending Dose Study of Safety and Tolerability of Sarilumab and Methotrexate in Japanese Patients With Rheumatoid Arthritis

PHASE1CompletedINTERVENTIONAL
Enrollment

61

Participants

Timeline

Start Date

April 30, 2013

Primary Completion Date

December 31, 2013

Study Completion Date

December 31, 2013

Conditions
Rheumatoid Arthritis
Interventions
DRUG

sarilumab SAR153191 (REGN88)

Pharmaceutical form:solution Route of administration: subcutaneous

DRUG

placebo

Pharmaceutical form:solution Route of administration: subcutaneous

DRUG

methotrexate

Pharmaceutical form:capsule Route of administration: oral

DRUG

folic acid

Pharmaceutical form:tablet Route of administration: oral

Trial Locations (2)

Unknown

Investigational Site Number 392001, Sendai

Investigational Site Number 392002, Sendai

Sponsors

Lead Sponsor

Sanofi
All Listed Sponsors
collaborator

Regeneron Pharmaceuticals

INDUSTRY

lead

Sanofi

INDUSTRY

NCT01850680 - Single Ascending Dose Study of Safety and Tolerability of Sarilumab and Methotrexate in Japanese Patients With Rheumatoid Arthritis | Biotech Hunter | Biotech Hunter